New York, New York (PRWEB) May 17, 2014
A Florida woman has become the most recent plaintiff to file a morcellator lawsuit (http://www.gynecaremorcellatorlawsuit.com/ ) that alleges the use of a power morcellator resulted in the spread of uterine cancer, Bernstein Liebhard LLP reports. According to her complaint, which was filed on May 7, 2014, in the U.S. District Court for the Southern District of Florida, the plaintiff underwent a laparoscopic supra-cervical hysterectomy at the Cleveland Clinic in April 2013, at which time a Storz Rotocut Morcellator was used to shred and remove uterine fibroids. It was later discovered that the device, which was manufactured by Karl Storz Endoscopy-America, had resulted in the spread of undetected endometrial stoma sarcoma into her abdominal cavity. Among other things, the lawsuit accuses Karl Storz Endoscopy-America of failing to warn that the use of power morcellation during laparoscopic hysterectomy and fibroid removal could cause the spread of uterine cancer.( Case No: 0:14-cv-61086-RSR)
“Our Firm has received numerous inquiries from women whose experiences with power morcellation echo the allegations contained in this lawsuit,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly spread by morcellation.
Morcellator Cancer Lawsuits
Power morcellators are surgical instruments used to shred and cut uterine tissue and fibroids into small pieces so that they can be removed from the body during minimally-invasive surgery. On April 17, 2014, a U.S. Food & Drug Administration (FDA) alert discouraged doctors from using the devices in laparoscopic hysterectomy and fibroid removals, because of the risk that they could promote the spread of undetected uterine sarcomas and other cancers. Roughly 1 in 350 women who undergo fibroid removal may also suffer from undiagnosed uterine cancers, the FDA said.
The FDA is planning to convene a meeting of its Obstetrics and Gynecological Medical Device Advisory Committee later this summer to further investigate the risks associated with uterine morcellation. Until the FDA is able to provide further guidance on the matter, Johnson & Johnson’s Ethicon unit has indicated it will suspend sales of its Gynecare Morcellex. Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products.* A number of hospitals, including the Cleveland Clinic, have also moved to bar or limit the technique until the FDA completes its review.**
Victims of uterine cancer that was allegedly spread via a power morcellator may be eligible for compensation. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling 800-511-5092.
*reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
**cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, Cleveland Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP